Clinical Trial Update: A Multi-Center Study to Evaluate the Efficacy and Safety of KX2-391 Ointment 1% on Actinic Keratosis on Face or Scalp (AK004) [Phase 3]

View source ↗

Summary

Phase 3 trial assessing the efficacy and safety of KX2-391 1% ointment for actinic keratosis on face or scalp completed with posted results.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Actinic Keratosis

Drugs mentioned

• KX2-391 Ointment 1%

Snippet

Sponsor: Almirall, S.A. | Conditions: Actinic Keratosis | Phase 3 | Status: COMPLETED | Results posted: 2021-03-10